Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism

Journal of Immunology

Volumn 162, Issue 8, 1999, Pages 4817-4823

  La Motte, Ross N ^a   Sharpe, Arlene H ^b   Bluestone, Jeffrey A ^c   Mokyr, Margalit B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD86 ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PHYCOERYTHRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 0033561755     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Janeway, C. A. J., and K. Bottomly. 1994. Signals and signs for lymphocyte responses. Cell 76:275.
2. Jenkins, M. K., and J. G. Johnson. 1993. Molecules involved in T-cell costimulation. Curr. Opin. Immunol. 5:361.
3. Bluestone, J. A. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555.
4. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065.
5. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, and J. A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173:721.
6. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177:1791.
7. + helper T cells. J. Exp. Med. 171:1315.
8. Chen, L., P. S. Linsley, and K. E. Hellström. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
9. Allison, J. P., A. A. Hurwitz, and D. R. Leach. 1995. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. 7:682.
10. + T cells by B7-transfected melanoma cells. Science 259:368.
11. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellström, and K. E. Hellström. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
12. Chen, L., S. Ashe, W. A. Brady, I. Hellström, K. E. Hellström, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093.
13. La Motte, R. N., M. A. Rubin, E. Barr, J. M. Leiden, J. A. Bluestone, and M. B. Mokyr. 1996. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. 42:161.
14. Gajewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
15. Matulonis, U., C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
16. Wu, T. C., A. Y. Huang, E. M. Jaffee, H. I. Levitsky, and D. M. Pardoll. 1995. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182:1415.
17. Townsend, S. E., F. W. Su, J. M. Atherton, and J. P. Allison. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477.
18. + cytolytic T lymphocytes. J. Exp. Med. 183:791.
19. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, K. S. Hathcock, G. Laszlo, A. J. McKnight, J. Kim, L. Du, D. B. Lombard, et al. 1993. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907.
20. Sharpe, A. H. 1995. Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Curr. Opin. Immunol. 7:389.
21. Peters, L. C., J. S. Brandhorst, and M. G. Hanna. 1979. Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res. 39:1353.
22. Berd, D., H. C. Maguire, and M. J. Mastrangelo. 1986. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46:2572.
23. Razi-Wolf, Z., G. J. Freeman, F. Galvin, B. Benacerraf, L. Nadler, and H. Reiser. 1992. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci. USA 89:4210.
24. Baskar, S., V. K. Clements, L. H. Glimcher, N. Nabavi, and S. Ostrand-Rosenberg. 1996. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J. Immunol. 156:3821.
25. Yang, G., M. T. Mizuno, K. E. Hellström, and L. Chen. 1997. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. J. Immunol. 158:851.
26. Nandi, D., J. A. Gross, and J. P. Allison. 1994. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J. Immunol. 152:3361.
27. Chambers, B. J., J. L. Wilson, M. Salcedo, K. Markovic, M. T. Bejarano, and H. G. Ljunggren. 1998. Triggering of natural killer cell mediated cytotoxicity by costimulatory molecules. Curr. Top. Microbiol. Immunol. 230:53.
28. Geldhof, A. B., G. Raes, M. Bakkus, S. Devos, K. Thielemans, and P. De Baetselier. 1995. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res. 55:2730.
29. Nishio, M., J. Spielman, R. K. Lee, D. L. Nelson, and E. R. Podack. 1996. CD80 (B7.1) and CD54 (intracellular adhesion molecule-1) induce target cell susceptibility to promiscuous cytotoxic T cell lysis. J. Immunol. 157:4347.
30. Rock, K. L. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17:131.
31. Brossart, P., and M. J. Bevan. 1997. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90:1594.
32. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
33. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
34. + T cell clones secrete the Th1 pattern of cytokines. J. Immunol. 144:1744.
35. + cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activity. J. Immunol. 143:379.
36. Huang, A. Y., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769.
37. Qin, Z., G. Noffz, M. Mohaupt, and T. Blankenstein. 1997. Interleukm-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159:770.